Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGB3 | P05106 | 18/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.71 |
| ▸ | ITGB8 | P26012 | 4/20 | 0.71 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.69 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.69 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432237 | 1.00 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8ITGB1 | |
| SCHEMBL6433051 | 1.00 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8ITGB1 | |
| SCHEMBL2786763 | 0.96 | ITGAV (0.93) | ITGAVITGB3ITGB6ITGB8ITGB1 | |
| SCHEMBL6431919 | 0.90 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGB1 | |
| SCHEMBL6431924 | 0.90 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGB1 | |
| SCHEMBL6432359 | 0.90 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGB1 | |
| SCHEMBL6434481 | 0.90 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGB1 | |
| SCHEMBL6432362 | 0.90 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGB1 | |
| SCHEMBL6432370 | 0.90 | ITGAV (0.81) | ITGAVITGB3ITGB6ITGB8ITGB1 | |
| SCHEMBL6432379 | 0.90 | ITGAV (0.81) | ITGAVITGB3ITGB6ITGB8ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040111-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-06-22 | — | — | EP | claimed |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2005-01-06 | — | — | US | claimed |
| EP-1349548-A4 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO INC (US) | 2004-06-02 | — | — | EP | claimed |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | HARTMAN GEORGE D (US) | 2004-03-18 | — | — | US | claimed |
| EP-1349548-A2 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | Merck & Co., Inc. (US) | 2003-10-08 | — | — | EP | claimed |
| EP-1322311-A1 | TREATMENT OF INFLAMMATION WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND AN INTEGRIN ALPHA-V ANTAGONIST | Merck & Co., Inc. (US) | 2003-07-02 | — | — | EP | claimed |
| WO-2002053099-A2 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO., INC. (US) | 2002-07-11 | — | — | WO | claimed |
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2002-04-04 | — | — | US | claimed |
| WO-2002022124-A1 | TREATMENT OF INFLAMMATION WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND AN INTEGRIN ALPHA-V ANTAGONIST | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | claimed |
| EP-1040111-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | claimed |
| WO-1999031099-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | claimed |
| US-9572801-B2 | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9572801-B2 | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160317527-A1 | TETRAHYDRONAPHTHYRIDINYL PROPIONIC ACID DERIVATIVES AND USES THEREOF | SCIFLUOR LIFE SCIENCES, INC. | 2016-11-03 | — | — | US | disclosed |
| WO-2016176532-A1 | TETRAHYDRONAPHTHYRIDINYL PROPIONIC ACID DERIVATIVES AND USES THEREOF | SCIFLUOR LIFE SCIENCES, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2002-04-04 | — | — | US | disclosed |
| WO-2002022124-A1 | TREATMENT OF INFLAMMATION WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND AN INTEGRIN ALPHA-V ANTAGONIST | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-1040111-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6017926-A | Integrin receptor antagonists | MERCK & CO., INC. (US) | 2000-01-25 | — | — | US | disclosed |
| WO-1999031099-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317527-A1 | TETRAHYDRONAPHTHYRIDINYL PROPIONIC ACID DERIVATIVES AND USES THEREOF | CPT1A, CFTR, SLC10A1 | ITGAV 838/4885ITGB3 711/4885ITGB6 968/4885 |
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | ITGAV, ITGA5, ITGA2 | ITGAV 1/4885ITGB3 9/4885ITGB6 15/4885 |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | ITGAV, ITGA5, ITGB5 | ITGAV 1/4885ITGB3 8/4885ITGB6 13/4885 |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | ITGB3, ITGB5, ITGB2 | ITGAV 11/4885ITGB3 1/4885ITGB6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.